SG/CALL/AMGEN/380/0.1/20.09.24 Stock

DE000SU6VRW4

Real-time Boerse Frankfurt Warrants 12:41:12 2024-06-11 pm EDT
0.09 ^EUR	-10.00%

Current month	-28.57%
1 month	-47.37%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Latest news about AMGEN INC.

Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	12:13pm	AQ
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar	10:14am	AQ
Transcript : Amgen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	Jun. 10
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	Jun. 10	AQ

More news

Quotes 5-day view

Date	Price	Change
24-06-11	0.09	-10.00%
24-06-10	0.1	-9.09%
24-06-07	0.11	-8.33%
24-06-06	0.12	-14.29%
24-06-05	0.14	0.00%

Real-time Boerse Frankfurt Warrants

Last update June 11, 2024 at 12:41 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Société Générale
WKN	SU6VRW
ISIN	DE000SU6VRW4
Date issued	2024-01-10
Strike	380 $
Maturity	2024-09-20 (101 Days)
Parity	10 : 1
Emission price	0.57 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.82 €
Lowest since issue	0.07 €
Spread	0.01 €
Spread %	10.00%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company